ZVRA - Zevra Therapeutics Inc.

Buy Momentum: Bearish

Recent News

Zevra Therapeutics ( ZVRA ) Reports Q2 Loss, Tops Revenue Estimates ( Revised )

Zacks Commentary • 4 weeks, 2 days ago • score: 0.19

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -44.75% and +14.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-09 (Snapshot)

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.

52W High

$13.16

52W Low

$6.19

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.56

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

11.32

EV/EBITDA (<8 favorable)

9.93

EV/Revenue (<3 favorable)

5.84

P/S (TTM) (<3 favorable)

8.10

P/B (<3 favorable)

4.29

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

0.69%

Institutions (25–75% balanced)

65.11%

Shares Outstanding

56,135,000

Float

46,909,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

62,020,000

Gross Profit (TTM)

44,627,000

EPS (TTM)

-0.25

Profit Margin (>10% good)

0.04%

Operating Margin (TTM) (higher better)

-0.48%

ROE (TTM) (>15% strong)

0.04%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

4.82

Momentum

Bearish momentum

Value

-0.5607

-0.5722

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025